Hi I'm pleased to present a brief video update on whats happening at MindBio.We recently reported a sustained anti-depressant response from microdosing MB220001 at 1 months and 3 months post cessation of an 8-week treatment cycle. Our women's health...

Hi We continue take-home dosing in two Phase 2B clinical trials with a third Phase 2B women's health trial recently approved for use of a microdose of a psychedelic medicine (MB22001) to treat mood symptoms in Premenstrual Syndrome and Premenstrual D...

Hi Please see release from MindBio Therapeutics below.Vancouver, British Columbia – July 8, 2024 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a leading biopharmaceutical company in psychiatric microdosing me...

Hi We are pleased to present secondary data from MindBio's Phase 2A Microdosing Depression Trial completed earlier this year.Data from MindBio’s Phase 2A Depression trial indicates improvements in a range of secondary outcome measures following an 8-...

Hi Please see latest news release posted today from MindBio and Enveric Biosciences.Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders.M...

Dr Rachael Sumner discusses Microdosing MB22001 for negative mood symptom relief in Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD).

Here is the link to the clinical trial paper on Sleep produced by MindBio scientific collaborators and published in Nature’s portfolio journal Translational Psychiatry:https://www.nature.com/articles/s41398-024-02900-4

Unlocking Market Potential: Leveraging Big Data Analytics to Revolutionize Depression Research

MindBio publishes positive Phase 2a Data in Landmark Depression Trial

Positive Phase 2a results reported in Depression trial. Permalink